OncoBeta® GmbH with its headquarters located in Garching, near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. OncoBeta® GmbH is European CE certified and has filed for regulatory approval in several other countries outside the EU.
Furthermore, having the patient in focus, OncoBeta® is enthusiastically working with medical, scientific and industrial partners as well as local and national authorities to make this personalized, painless and non-invasive therapy accessible to patients all over the world. The Rhenium-SCT® significantly improves outcomes and the quality of life of non-melanoma skin cancer patients.
OncoBeta® GmbH is very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Future oriented, we seek, develop and deliver therapies which provide painless, customized, single-session applications that achieve exceptional cosmetic results.
Our highly advanced and effective Rhenium-SCT® (Skin Cancer Therapy) was created in collaboration with the wants and needs expressed by physicians and their patients as well as a strong emphasis on economic and ethical criteria.
Our current mission is to continuously improve the quality of life of patients suffering from non-melanoma skin cancer, the world’s most common cancer.
Our primary goal is to offer an effective, customized and non-invasive treatment, independent of tumour size, severity and localization. Providing a fast, painless, single treatment, with no side effects and aesthetic results.
We do this by further developing our innovative therapeutic applications with the use of modern radioisotopes and state-of-the-art application equipment achieving genuine added value with an extreme emphasis on ethical and economic criteria.
We are working relentlessly to increase our current therapeutic portfolio, while constantly striving to develop additional non-invasive therapies in the areas of dermatology and oncology for patients in need.
A strong desire to alleviate suffering and be able to walk in the shoes of the people we server and work with.
Developing effective and personalized solutions for physicians and their patients.
Demonstrating excellence in everything we do.
Showing regard, consideration and thankful recognition to each other.
Cooperative and coordinated efforts in the interests of our common cause.
Focus on the job at hand to improve the quality of treatment and/or service.
Adherence to moral and ethical principles, honour commitments and never compromise ethics in all our dealings.
Being open and truthful in all things we do.